Cardinal Capital Management Inc. Has $1.16 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Cardinal Capital Management Inc. lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 37.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,575 shares of the biopharmaceutical company’s stock after selling 7,673 shares during the quarter. Cardinal Capital Management Inc.’s holdings in Gilead Sciences were worth $1,162,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Goldstein Advisors LLC acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $218,000. Avior Wealth Management LLC boosted its stake in Gilead Sciences by 33.2% in the fourth quarter. Avior Wealth Management LLC now owns 12,551 shares of the biopharmaceutical company’s stock worth $1,140,000 after purchasing an additional 3,129 shares in the last quarter. Beacon Investment Advisory Services Inc. increased its stake in shares of Gilead Sciences by 4.7% in the fourth quarter. Beacon Investment Advisory Services Inc. now owns 80,232 shares of the biopharmaceutical company’s stock valued at $7,411,000 after buying an additional 3,637 shares in the last quarter. Bartlett & CO. Wealth Management LLC raised its holdings in shares of Gilead Sciences by 149.1% in the fourth quarter. Bartlett & CO. Wealth Management LLC now owns 8,697 shares of the biopharmaceutical company’s stock valued at $803,000 after buying an additional 5,205 shares during the last quarter. Finally, Albion Financial Group UT lifted its position in Gilead Sciences by 182.7% during the 4th quarter. Albion Financial Group UT now owns 783 shares of the biopharmaceutical company’s stock worth $72,000 after buying an additional 506 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the sale, the chief financial officer now directly owns 138,919 shares in the company, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 456,234 shares of company stock valued at $42,130,461. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Maxim Group cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Truist Financial boosted their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Finally, Oppenheimer upped their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $97.96.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $93.04 on Thursday. The stock has a fifty day moving average of $91.63 and a 200-day moving average of $84.63. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The stock has a market capitalization of $115.95 billion, a P/E ratio of 1,033.78, a price-to-earnings-growth ratio of 1.31 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter in the prior year, the firm posted $2.29 earnings per share. The business’s quarterly revenue was up 7.0% on a year-over-year basis. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.31%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.